AllerGenis, LLC has entered into a non-exclusive agreement with Luminex Corporation, for the rights to use Luminex's xMAP technology in its precision food allergy diagnostic platform. According to the terms, AllerGenis will have the rights to develop, market and sell its novel precision food allergy diagnostic assay using Luminex's xMAP Technology. AllerGenis peanut allergy assay will be the first product to launch supported by this agreement in the fall of 2019. This agreement enables AllerGenis to develop and market food allergy diagnostic using xMAP technology.